Clinical Trial Update: Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of bortezomib, dexamethasone, and doxorubicin with ALCAR in previously treated multiple myeloma completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ALCAR (acetyl-L-carnitine)
• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Doxorubicin (doxorubicin)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2016-08-24